Article (Scientific journals)
Development of pure prolactin receptor antagonists
Bernichtein, Sophie; Kayser, Christine; Dillner, Karin et al.
2003In Journal of Biological Chemistry, 278 (38), p. 35988-99
Peer Reviewed verified by ORBi
 

Files


Full Text
Development of pure prolactin receptor antagonists.pdf
Publisher postprint (573.18 kB)
Download

2003/06/26


All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Amino Acid Motifs; Animals; Binding, Competitive; Biological Assay; Cell Division; Cell Line; DNA-Binding Proteins/metabolism; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Escherichia coli/metabolism; Hormones/metabolism; Humans; Inhibitory Concentration 50; Liver/enzymology; MAP Kinase Signaling System; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; *Milk Proteins; Mutagenesis, Site-Directed; Plasmids; Precipitin Tests; Prolactin/*chemistry/pharmacology; Promoter Regions, Genetic; Prostate/metabolism; Protein Binding; Protein Structure, Tertiary; Radioimmunoassay; Rats; Receptors, Prolactin/*antagonists & inhibitors/chemistry; Recombinant Proteins/metabolism; STAT5 Transcription Factor; Signal Transduction; Trans-Activators/metabolism; Transcription, Genetic
Abstract :
[en] Prolactin (PRL) promotes tumor growth in various experimental models and leads to prostate hyperplasia and mammary neoplasia in PRL transgenic mice. Increasing experimental evidence argues for the involvement of autocrine PRL in this process. PRL receptor antagonists have been developed to counteract these undesired proliferative actions of PRL. However, all forms of PRL receptor antagonists obtained to date exhibit partial agonism, preventing their therapeutic use as full antagonists. In the present study, we describe the development of new human PRL antagonists devoid of agonistic properties and therefore able to act as pure antagonists. This was demonstrated using several in vitro bioassays, including highly sensitive assays able to detect extremely low levels of receptor activation. These new compounds also act as pure antagonists in vivo, as assessed by analyzing their ability to competitively inhibit PRL-triggered signaling cascades in various target tissues (liver, mammary gland, and prostate). Finally, by using transgenic mice expressing PRL specifically in the prostate, which exhibit constitutively activated signaling cascades paralleling hyperplasia, we show that these new PRL analogs are able to completely revert PRL-activated events. These second generation human PRL antagonists are good candidates to be used as inhibitors of growth-promoting actions of PRL.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Bernichtein, Sophie;  INSERM Unit 584
Kayser, Christine;  INSERM Unit 584
Dillner, Karin;  Karolinska Institute > Department of Molecular Medicine
Moulin, Stéphanie;  INSERM Unit 584
Kopchick, John J.;  Ohio University > Edison Biotechnology Institute, Molecular and Cellular Biology Program, and Department of Biomedical Sciences > College of Osteopathic Medicine
Martial, Joseph ;  Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Norstedt, Gunnar;  Karolinska Institute > Department of Molecular Medicine
Isaksson, Olle;  Göteborg University > Department of Internal Medicine > Sahlgrenska University Hospital
Kelly, Paul A.;  INSERM Unit 584
Goffin, Vincent;  INSERM Unit 584
Language :
English
Title :
Development of pure prolactin receptor antagonists
Publication date :
2003
Journal title :
Journal of Biological Chemistry
ISSN :
0021-9258
eISSN :
1083-351X
Publisher :
American Society for Biochemistry and Molecular Biology, Baltimore, United States - Maryland
Volume :
278
Issue :
38
Pages :
35988-99
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 20 May 2009

Statistics


Number of views
78 (3 by ULiège)
Number of downloads
199 (0 by ULiège)

Scopus citations®
 
105
Scopus citations®
without self-citations
45
OpenCitations
 
86

Bibliography


Similar publications



Contact ORBi